Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eli Lilly and Company
Stemline Therapeutics, Inc.
Bristol-Myers Squibb
Eli Lilly and Company
Pathos AI, Inc.
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Novartis
Thomas Jefferson University
BeiGene
Atara Biotherapeutics
Kyowa Kirin Co., Ltd.
Steba Biotech S.A.
Revolution Medicines, Inc.
Advanced Accelerator Applications
Isofol Medical AB
Life Molecular Imaging SA
AVEO Pharmaceuticals, Inc.
BBB-Therapeutics B.V.